Marjolin ulcer is a rare and aggressive skin cancer that arises in chronically damaged tissue, most often old burn scars or wounds that never fully healed. The malignancy is overwhelmingly squamous cell carcinoma, and it behaves more aggressively than the typical squamous cell cancers that develop on sun-exposed skin. What makes Marjolin ulcer particularly dangerous is its deceptive origin: a scar or wound that has been stable for years, sometimes decades, quietly undergoes malignant transformation, and the cancer often goes unrecognized until it is advanced.
How Burn Scars and Chronic Wounds Become Cancer
The defining feature of a Marjolin ulcer is that it does not arise on normal skin. It grows out of tissue that has been injured or inflamed for a long time. Burn scars are by far the most common precursor, accounting for roughly two-thirds to over 80% of cases depending on the population studied.1PubMed Central. Marjolin’s ulcer in chronic wounds – review of available literature2The Kaohsiung Journal of Medical Sciences. Clinicopathological evaluation of Marjolin ulcers over two decades But burns are not the only trigger. Marjolin ulcers have also been documented in pressure sores, venous leg ulcers, chronic osteomyelitis sinuses, traumatic wounds, and areas previously treated with radiation.3PubMed. Multiple Marjolin’s ulcers arising from irradiated post-burn hypertrophic scars: a case report The common thread is tissue that has been locked in a cycle of injury and incomplete repair for years.
The exact biological mechanism behind the transformation is not fully mapped, but researchers have identified several contributors. Scar tissue has reduced blood supply and impaired immune surveillance, meaning the body’s usual tools for catching and eliminating abnormal cells are weakened in these areas. Chronic inflammation drives repeated cell division, and each round of division introduces opportunities for DNA damage to accumulate. Gene-expression analyses of Marjolin ulcer tissue show disruptions in cell-cycle regulation, immune-response pathways, and the p53 signaling pathway, a key tumor-suppression system that normally prevents damaged cells from multiplying unchecked.4PubMed Central. Comprehensive Analysis of Long Noncoding RNAs and Messenger RNAs Expression Profiles in Patients with Marjolin Ulcer In short, chronically damaged skin is an environment where cancer has an easier time taking root and hiding.
The Decades-Long Waiting Period
One of the most striking things about Marjolin ulcer is how long it takes to appear after the original injury. The latency period, from initial wound to cancer diagnosis, averages roughly 28 to 32 years across major case series. A study of 140 cases at a burn center in China reported a mean latency of about 29 years, while a separate series found a mean of about 32 years.5PubMed Central. Clinical features and treatment of 140 cases of Marjolin’s ulcer at a major burn center in southwest China6Journal of Burn Care & Research. The Fate of Chronic Burn Wounds Suspected as Marjolin’s Ulcers A systematic review of 14 modern case series found the median latency was 28 years, with ranges spanning from 11 to 41 years depending on the series.7PubMed Central. Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin
That said, the “classic” decades-long delay is not universal. Some patients develop Marjolin ulcer much sooner. Cases with latency periods under two years have been documented, and one report described invasive squamous cell carcinoma appearing just six months after the initial injury.8PubMed Central. Post-traumatic acute Marjolin ulcer with a short latency period in a young man: a case report These acute cases are rare, but they complicate the assumption that only very old scars are at risk. Any non-healing or changing wound deserves attention, regardless of how recently the original injury occurred.
Who Is Most Affected
Marjolin ulcers are more common in men and typically diagnosed around the fifth decade of life, which aligns with the long latency: someone burned as a child or young adult might not develop cancer in the scar until their 40s or 50s.9PubMed Central. Marjolin ulcer: a rare clinical entity that every health professional should be informed about: a narrative review The lower extremities are the most common site on the body, involved in roughly 40% to over 60% of cases.10PubMed Central. Marjolin’s ulcers at a university teaching hospital in Northwestern Tanzania: a retrospective review of 56 cases11PubMed Central. Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin This makes sense when you consider that the legs are particularly vulnerable to burns, chronic venous ulcers, and slow-healing wounds.
The global distribution is heavily skewed. In a systematic review of nearly 600 patients across 14 case series, about 82% came from low-income and middle-income countries.12PubMed Central. Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin The reasons are straightforward: limited access to burn treatment, delayed or inadequate wound care, and fewer opportunities for follow-up mean that chronic wounds persist longer and malignant changes go undetected. In high-income countries where burn care and wound management are more accessible, the condition is much less frequently seen, though it still occurs.
Recognizing the Warning Signs
The challenge with Marjolin ulcer is that it disguises itself inside an already abnormal-looking wound or scar. A patient may have lived with a scarred, occasionally irritated area for years, so new changes can be easy to dismiss. The warning signs to watch for in any chronic wound or old burn scar include:
- New ulceration: a scar that was previously flat or stable begins to break down and form an open wound.
- Raised or rolled edges: the borders of a wound become firm, thickened, or elevated, rather than healing inward.
- Rapid growth: a wound that had been static for years starts expanding noticeably.
- Pain change: a painless scar that becomes painful, or a painful wound whose character of pain shifts.
- Foul-smelling discharge: persistent bad-smelling drainage, especially if bleeding increases.
- Failure to heal: a wound that resists treatment and does not close with standard wound care.
Any of these changes should prompt a biopsy rather than watchful waiting. The consensus among clinicians is clear: early biopsy at the first sign of suspicious change improves both prognosis and survival.13PubMed Central. Marjolin ulcer: a rare clinical entity that every health professional should be informed about: a narrative review Given that the mortality rate for Marjolin ulcer averages around 20%, delays in diagnosis carry real consequences.
What Biopsy and Imaging Reveal
Tissue biopsy is the definitive diagnostic step. Squamous cell carcinoma accounts for the vast majority of Marjolin ulcers, but the spectrum is wider than many clinicians expect. In a review of 83 cases, well-differentiated squamous cell carcinoma made up about 39% of diagnoses, with moderately and poorly differentiated forms adding another 19%. But nearly 10% were basal cell carcinoma, and smaller numbers turned out to be melanoma, verrucous carcinoma, or other rare malignancies.14PubMed Central. Marjolin’s ulcer: clinical and pathologic features of 83 cases and review of literature This variety underscores why biopsy is non-negotiable: the treatment approach can change significantly depending on the specific cancer type and its differentiation grade.
Once malignancy is confirmed, imaging helps determine how deeply the cancer has invaded. MRI is particularly useful for showing soft-tissue extent, tumor margins, and whether bone or nearby blood vessels are involved. Plain radiography can reveal bone destruction underneath the ulcer, which is important when the cancer sits over a joint or bony prominence.15PubMed Central. Marjolin’s Ulcer: Radiographic and magnetic resonance appearances in two cases PET/CT scanning has also been investigated for staging, particularly to evaluate whether the cancer has spread to lymph nodes or distant sites.16PubMed. Role of 18F-FDG PET/CT in the diagnosis of clinically suspected Marjolin ulcer
The Lymph Node Problem
Staging Marjolin ulcer, specifically figuring out whether cancer has spread to regional lymph nodes, is trickier than for most skin cancers. In the systematic review of 14 modern series, almost a third of patients appeared clinically node-positive based on physical exam, but only about 7% were confirmed to have actual pathological involvement when the nodes were examined under the microscope.17PubMed Central. Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin That gap likely reflects chronic inflammatory lymph node enlargement being mistaken for metastatic disease, a problem unique to cancers arising in chronically inflamed tissue.
Sentinel lymph node biopsy, the standard minimally invasive technique for detecting hidden spread in many skin cancers, faces a unique obstacle with Marjolin ulcers. The extensive scarring from the original burn or wound disrupts lymphatic drainage pathways, making it hard for the tracer dye or radioactive marker to travel to the correct node. In a small series of six patients, sentinel node biopsy was successful in five, and four of those five revealed previously undetected metastases, suggesting the technique can find hidden disease when it works.18PubMed. Sentinel lymph node biopsy identifies occult nodal metastases in patients with Marjolin’s ulcer However, other investigators have concluded that lymphatic mapping simply does not work reliably in areas of extensive burn scarring, because the lymphatic channels are too damaged to carry the tracer.19PubMed. Sentinel node mapping in Marjolin’s ulcers: is it feasible? This remains an unresolved question in the field: there is no consensus on the best way to stage lymph nodes in Marjolin ulcer patients, and the answer may depend on how much surrounding scar tissue exists.
Surgical Treatment and Reconstruction
Wide surgical excision is the standard treatment. Surgeons typically aim for margins of at least two centimeters around the visible tumor, and the surrounding scar tissue is also excised aggressively, often down to healthy tissue beneath.20PubMed Central. Marjolin’s Ulcer Reconstruction With Free Anterolateral Thigh Flap: A Case Series of 11 Patients Frozen-section analysis during surgery allows pathologists to check the margins in real time: if cancer cells are found at the edge of the excised tissue, more tissue is removed immediately. When lymph nodes are clinically enlarged and suspicious, formal lymph node dissection is performed.21PubMed. Marjolin ulcer: clinical experience with 34 patients over 15 years
The resulting wound defects can be substantial, especially on the limbs, where these cancers are most common. Reconstruction ranges from skin grafts for smaller defects to complex free-flap surgery for larger ones. In one published series, all defects were reconstructed with free anterolateral thigh flaps taken from the opposite leg. When blood vessels near the tumor were involved, a “flow-through” flap was used to restore circulation and potentially avoid amputation.22PubMed Central. Marjolin’s Ulcer Reconstruction With Free Anterolateral Thigh Flap: A Case Series of 11 Patients Amputation is reserved for cases where the cancer has deeply invaded bone, joints, or major vessels and limb-sparing surgery is not feasible.
For patients whose disease is inoperable, or for high-risk cases after surgery, adjuvant radiation therapy and chemotherapy may be considered.23Saudi Journal of Medicine and Public Health. Marjolin Ulcer: Pathogenesis, Clinical Features, and Management in Chronic Wounds-An Updated Review The evidence base for these treatments in Marjolin ulcer specifically is thin compared to standard skin cancers, largely because the condition is rare and randomized trials are essentially nonexistent. Treatment decisions tend to be guided by multidisciplinary tumor boards, adapting protocols from conventional squamous cell carcinoma management.
Prognosis and What Drives Outcomes
Marjolin ulcer carries a worse prognosis than ordinary squamous cell carcinoma of the skin. It has higher rates of regional metastasis and a fatality rate that averages around 20%.24PubMed Central. Marjolin’s Ulcer Presenting with In-Transit Metastases: A Case Report and Literature Review25PubMed Central. Marjolin ulcer: a rare clinical entity that every health professional should be informed about: a narrative review Distant metastasis is less common, reported at a median rate of about 5% across series that tracked it, though individual series ranged from zero to 27%.26PubMed Central. Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin
A meta-analysis and systematic review identified several factors that predict worse outcomes. The features linked to higher recurrence and disease-specific death include:
- Tumor location: cancers on the head, neck, or upper limbs recur more often than those on the lower body.
- Large tumor size: tumors over 10 centimeters in diameter carry higher recurrence and mortality risk.
- High histologic grade: poorly differentiated cancers behave more aggressively than well-differentiated ones.
- Lymph node involvement: confirmed spread to lymph nodes significantly worsens the outlook.
- Treatment with amputation: somewhat counterintuitively, patients who underwent amputation had higher recurrence rates than those treated with wide excision alone, likely because amputation cases represent more advanced disease at the time of surgery.
These findings come from pooled data across published series, and the amputation finding in particular reflects selection bias rather than amputation itself being harmful.27Plastic & Reconstructive Surgery. Prognostic Factors of Marjolin Ulcers: A Meta-Analysis and Systematic Review Assisted by Machine Learning Techniques
Why Awareness Matters More Than Rarity Suggests
Because Marjolin ulcer is uncommon, many healthcare providers outside specialized burn or wound-care centers have never personally encountered one. That unfamiliarity is itself a clinical hazard. The condition was first described nearly two centuries ago, with the French surgeon Jean-Nicolas Marjolin credited with identifying cancerous degeneration in burn scars in 1828.28PubMed Central. Marjolin ulcer: an overlooked entity Yet it remains frequently overlooked. Clinicians may treat a non-healing wound for months with dressings and antibiotics before considering the possibility of malignancy, and patients themselves may attribute worsening symptoms to the scar “acting up” rather than something new.
The practical takeaway is simple enough for anyone with a chronic wound or old burn scar: changes matter. A wound that was stable for years and begins to break down, grow, bleed, or smell differently should not be managed with more of the same wound care. It should be biopsied. Given the long latency of these cancers, anyone who suffered a significant burn or deep wound earlier in life carries some degree of lifelong risk in that area of skin. Periodic inspection of old scars, even if they seem healed, is a reasonable habit.
When the Whole Scar Is the Problem
An underappreciated aspect of Marjolin ulcer management is that the cancer does not just occupy the visible ulcer; the surrounding scar tissue is itself considered pre-malignant or at least at elevated risk. This is why surgical excision extends well beyond the obvious tumor margins to include surrounding scar tissue wherever possible. Even after successful treatment, new Marjolin ulcers can develop in remaining scar tissue at the same or nearby sites. The aggressiveness of the malignancy, combined with the unreliability of lymph node staging and the difficulty of ensuring clear margins in scarred anatomy, is why some investigators have described Marjolin ulcer as a “preventable complication of burns” rather than an unavoidable fate.29Plastic and Reconstructive Surgery. Marjolin’s Ulcer: A Preventable Complication of Burns? In their framing, better initial burn care, earlier scar excision and grafting, and systematic long-term follow-up could prevent many cases from ever occurring. Given that the overwhelming majority of patients come from settings with limited access to burn care, the condition sits at an intersection of oncology, wound care, and global health equity that makes it difficult to address with any single intervention.